Rastogi Shruti, Kalaivani M, Bhatia Amandeep K, Prakash Jai, Singh G N
1 Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Ghaziabad, India.
Ther Innov Regul Sci. 2015 Sep;49(5):750-755. doi: 10.1177/2168479015572371.
Quality and safety tests are required for regulatory approval of drugs and pharmaceuticals in the country to guarantee minimum safety standards, and most of these tests include animal usage. In the case of biological medicines, these safety and quality tests have to be performed on a batch-to-batch basis and require a large number of animals. Russell and Burch's 1959 principle of the 3 Rs- replacement, reduction, and refinement-is now being increasingly adopted worldwide, and various national and international pharmacopoeias have taken initiatives to safeguard animals. This article details the Indian Pharmacopoeia Commission's initiative to implement the 3 Rs through the Indian Pharmacopoeia. Explored are the deletion of animal tests, such as the abnormal toxicity test at final lot for biologicals; the replacement of in vivo methods by in vitro methods; the reduction in the number of animals used where deletion of the animal test is not possible; and the refinement of tests to cause minimal suffering to the animals. In Indian Pharmacopoeia 2014, pyrogen testing using rabbits has been replaced by the bacterial endotoxin test in the majority of biological monographs-keeping in view international trends and, especially for vaccine monographs, validated in vitro tests such as the bacterial endotoxin test as an alternative to the pyrogen test where justified and authorized. Steps are taken for introducing a single-dilution assay for the potency testing of diphtheria and tetanus vaccine (adsorbed) with the aim of minimizing number of animals used. The justified and authorized use of animals in drug manufacturing, analytic laboratories, and research will not only help in the expedited development/production of drugs but also be useful in protecting and promoting animal health.
在该国,药品和药剂的监管审批需要进行质量和安全测试,以确保最低安全标准,而这些测试大多涉及动物使用。就生物药品而言,这些安全和质量测试必须逐批进行,并且需要大量动物。罗素和伯奇在1959年提出的3R原则——替代、减少和优化——如今在全球范围内得到越来越广泛的采用,各国和国际药典也已采取举措保护动物。本文详细介绍了印度药典委员会通过《印度药典》实施3R原则的举措。探讨了删除动物试验,如生物制品成品批异常毒性试验;用体外方法替代体内方法;在无法删除动物试验的情况下减少动物使用数量;以及优化试验以尽量减少动物的痛苦。在《2014年印度药典》中,考虑到国际趋势,大多数生物制品专论中使用兔子进行的热原试验已被细菌内毒素试验取代,尤其是对于疫苗专论,在合理且获得授权的情况下,已验证的体外试验如细菌内毒素试验可替代热原试验。已采取措施引入白喉和破伤风疫苗(吸附)效价检测的单稀释法,以尽量减少动物使用数量。在药品生产、分析实验室和研究中合理且获得授权地使用动物,不仅有助于加快药物的研发/生产,还有助于保护和促进动物健康。